Compare HTCR & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | PULM |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 13.6M |
| IPO Year | 2022 | N/A |
| Metric | HTCR | PULM |
|---|---|---|
| Price | $0.33 | $2.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 197.6K | 28.7K |
| Earning Date | 11-18-2025 | 10-16-2025 |
| Dividend Yield | ★ 41.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,189,136.00 | $3,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | $134.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $2.22 |
| 52 Week High | $3.38 | $10.40 |
| Indicator | HTCR | PULM |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 24.82 |
| Support Level | $0.31 | $2.22 |
| Resistance Level | $0.38 | $4.94 |
| Average True Range (ATR) | 0.04 | 0.42 |
| MACD | 0.00 | -0.20 |
| Stochastic Oscillator | 46.22 | 4.02 |
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).